ArticleDiscover oncology2025
Arginine methylation patterns in LUAD: defining prognostic subtypes and relevance to immunotherapy.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLung cancer remains the leading cause of cancer-related death worldwide, with lung adenocarcinoma (LUAD) being the most common subtype. Arginine methylation, driven by protein arginine methyltransferases (PRMTs) has been connected to cancer biology, particularly in modulating cancer immunity. Thus, developing a PRMTs-related prognostic model might help create more personalized treatment plans for LUAD patients.
methodsWe conducted an integrative analysis using multi-omics data from LUAD samples within the TCGA and GEO database, focusing on the expression profiles of nine PRMTs. Employing machine learning, we developed a PRMTs-related prognostic model, to evaluate the clinical and immunological features of LUAD patients.
resultsWe stratified 440 LUAD patients into two distinct clusters (PRMTCluster A and B), which exhibited significant differences in prognosis and immune infiltration. The PRMTs-related prognostic model, incorporating genes CLIC6, CLDN2, and BPIFB1, was significantly associated with patient outcomes and immune signature. RT-qPCR showed that the expression level of PRMT1, PRMT3, PRMT4, PRMT5, and PRMT7 was significantly upregulated in H1975 and A549 cells than in BEAS 2B cells.
conclusionWe developed a PRMTs-related prognostic model for assessing prognosis and immunotherapy responses in LUAD. This model was vital for developing more personalized and effective treatment plans for LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.